cbdMD Inc. saw a price increase of 10.84% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.
This surge is attributed to the company's recent operational improvements, including a $2.25 million capital raise through the issuance of Series C Convertible Preferred Stock, which strengthens its balance sheet and supports future growth initiatives. The company reported a reduced operating loss of $2.1 million for fiscal 2025, showcasing ongoing progress in cost management and execution, which enhances confidence in future profitability.
The implications of these developments suggest that cbdMD is positioning itself for sustained growth in the competitive CBD market, particularly as it expands its distribution and product offerings, indicating a positive outlook for investors.
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast YCBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YCBD is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.754
Low
2.00
Averages
2.00
High
2.00
Current: 0.754
Low
2.00
Averages
2.00
High
2.00
Maxim
Buy
downgrade
$3 -> $2
2025-08-20
Reason
Maxim
Price Target
$3 -> $2
AI Analysis
2025-08-20
downgrade
Buy
Reason
Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.
Maxim
Buy
downgrade
$16 -> $3
2025-05-22
Reason
Maxim
Price Target
$16 -> $3
2025-05-22
downgrade
Buy
Reason
About YCBD
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
